NH company shines light on UV therapy for autoimmune conditions
Started in 2021, Cytokind describes itself as 'the global leader in using UVB light to treat immune disorders and improve survival and the quality of life for patients'
iCAD reports another quarterly loss
But revenues have been climbing so far this year
Nashua-based iCAD Inc. is reporting another quarterly loss – this time $589,000, or 5 cents a share.
However the company, which uses radiation to both detect and treat cancer, emphasized that year-to-date revenue is up 17 percent, despite it being relatively flat during the third quarter. It also said quarterly losses were nearly a third of what they were during the same quarter last year, and more than half what they were for the first three quarters of 2012.
The company total revenue was $8.3 million for the quarter ending Sept. 30, a little more than $100,000 more than the third quarter of 2012. This is primarily because of 14 percent increase in cancer detection revenue, the company legacy business.
That was offset, however, by a 10 percent decline in revenue from iCAD’s cancer treatment technology, added when it acquired Xoft in 2010.
Year to date, the company has reported it’s in the red by $3.2 million, or 30 cents a share, for the first three quarters of the year.
